Adjuvant Medications That Improve Survival after Locoregional Therapy.

ABSTRACT:

Purpose

To determine if outpatient medications taken at the time of liver tumor embolization or ablation affect survival.

Materials and methods

A retrospective review was done of 2,032 liver tumor embolization, radioembolization, and ablation procedures performed in 1,092 patients from June 2009 to April 2016. Pathology, hepatocellular carcinoma (HCC) stage (American Joint Committee on Cancer), neuroendocrine tumor (NET) grade, initial locoregional therapy, overall survival after initial locoregional therapy, Child-Pugh score, Eastern Cooperative Oncology Group performance status, Charlson Comorbidity Index, and outpatient medications taken at the time of locoregional therapy were analyzed for each patient. Kaplan-Meier survival curves were calculated for patients taking 29

SUBMITTER: Boas FE 

PROVIDER: S-EPMC5502720 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature